Emergent Biosolutions (EBS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2022 | 12-2021 | 09-2021 | 06-2021 | 03-2021 | |
| Sales | 307,500 | 704,100 | 329,000 | 397,500 | 343,000 |
| Cost of Goods | 155,900 | 203,500 | 217,500 | 227,800 | 99,300 |
| Gross Profit | 151,600 | 500,600 | 111,500 | 169,700 | 243,700 |
| Operating Expenses | 146,100 | 234,900 | 146,700 | 156,000 | 148,600 |
| Operating Income | 6,400 | 266,200 | -34,700 | 14,500 | 95,400 |
| Interest Expense | 8,200 | 9,000 | 8,400 | 8,600 | 8,500 |
| Other Income | -2,000 | -900 | -2,400 | 1,300 | -1,700 |
| Pre-tax Income | -3,800 | 256,300 | -45,500 | 7,200 | 85,200 |
| Income Tax | -100 | 78,400 | -12,800 | 2,600 | 15,500 |
| Net Income Continuous | -3,700 | 177,900 | -32,700 | 4,600 | 69,700 |
| Net Income | $-3,700 | $177,900 | $-32,700 | $4,600 | $69,700 |
| EPS Basic Total Ops | -0.07 | 3.31 | -0.61 | 0.09 | 1.31 |
| EPS Basic Continuous Ops | -0.07 | 3.32 | -0.61 | 0.09 | 1.31 |
| EPS Diluted Total Ops | -0.07 | 3.30 | -0.61 | 0.09 | 1.28 |
| EPS Diluted Continuous Ops | -0.07 | 3.30 | -0.61 | 0.09 | 1.28 |
| EBITDA(a) | $38,300 | $338,100 | $-900 | $48,700 | $125,100 |